Back
 IJCM  Vol.10 No.4 , April 2019
Virilizing Ovarian Leydig Cell Tumor with Multiple Non-Functional Endocrine Neoplasias: A Case Report
Abstract: Ovarian Leydig cell tumor, a sub-type of ovarian steroid cell tumor, accounts for less than 0.1% of all ovarian tumors. It can affect women of any age group but is most common in postmenopausal women. We here report a case of virilizing ovarian Leydig cell tumor with multiple non-functional endocrine neoplasias (pituitary and adrenal adenomas) in a 48-year-old woman. She first presented with sub-abdominal pain and hirsutism since menopause three years ago. Subsequently, she had slight facial acne, voice deepening, breast atrophy, and a prominent Adam’s apple. Her hormone profile showed an elevated level of testosterone, high free androgen index, low levels of luteinizing hormone and follicle stimulating hormone, and normal levels of random cortisol, androstenedione, 17-hydroxyprogesterone and dehydroepiandrosterone sulfate. A pelvic enhanced magnetic resonance imaging (MRI) scan showed nodules in the right ovary, and a pituitary enhanced MRI revealed a microadenoma. An enhanced computerized tomography scan of the adrenal gland revealed left adrenal nodules, possibly adenomas. After a right cystectomy and right fallopian tube resection, her testosterone level declined to 0.38 nmol/L and the symptoms associated with hyperandrogenism improved. This is a rare case of virilizing ovarian Leydig cell tumor with multiple non-functional endocrine neoplasias. We believe our findings will be helpful in the clinical diagnosis and treatment of hyperandrogenism.
Cite this paper: Xie, Y. , Zhong, S. , Zhou, Q. , Huang, Z. , Song, X. and Xu, X. (2019) Virilizing Ovarian Leydig Cell Tumor with Multiple Non-Functional Endocrine Neoplasias: A Case Report. International Journal of Clinical Medicine, 10, 306-315. doi: 10.4236/ijcm.2019.104023.
References

[1]   Youssef, A., Ben Ghezala, M., Oueslati, A., Agrebi, W. and Oueslati, H. (2006) Sertoli-Leydig Cell Tumor of the Ovary. La Tunisie Médicale, 84, 209-211.

[2]   Diab, D.L., Faiman, C., Siperstein, A.E., Grossman, W.F., Rabinowitz, L.O. and Hamrahian, A.H. (2008) Virilizing Ovarian Leydig Cell Tumor in a Woman with Subclinical Cushing Syndrome. Endocrine Practice, 14, 358-361.
https://doi.org/10.4158/EP.14.3.358

[3]   Rosenfield, R.L. (2005) Clinical Practice. Hirsutism. The New England Journal of Medicine, 353, 2578-2588.
https://doi.org/10.1056/NEJMcp033496

[4]   Glintborg, D., Altinok, M.L., Petersen, K.R. and Ravn, P. (2015) Total Testosterone Levels Are often more than Three Times Elevated in Patients with Androgen-Secreting Tumours. BMJ Case Reports, 2015, bcr2014204797.
https://doi.org/10.1136/bcr-2014-204797

[5]   Practice Committee of the American Society for Reproductive Medicine (2006) The Evaluation and Treatment of Androgen Excess. Fertility and Sterility, 86, S241-247.
https://doi.org/10.1016/j.fertnstert.2006.08.042

[6]   Sherf, S. and Martinez, D. (2017) Leydig Cell Tumor in the Post-Menopausal Woman: Case Report and Literature Review. Acta BioMedica, 87, 310-313.

[7]   Schlosser, R., Schafer, J. and Kaufmann, R. (2012) Heterozygous 21-Hydroxylasedefi-ciency as a Cause of Hyperandrogenism. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 10, 841-842.
https://doi.org/10.1111/j.1610-0387.2012.08013.x

[8]   Turcu, A.F. and Auchus, R.J. (2015) The Next 150 Years of Congenital Adrenal Hyperplasia. The Journal of Steroid Biochemistry and Molecular Biology, 153, 63-71.
https://doi.org/10.1016/j.jsbmb.2015.05.013

[9]   Speiser, P.W., Azziz, R., Baskin, L.S., Ghizzoni, L., Hensle, T.W., Merke, D.P., Meyer-Bahlburg, H.F., Miller, W.L., Montori, V.M., Oberfield, S.E., Ritzen, M. and White, P.C. (2010) Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 95, 4133-4160.
https://doi.org/10.1210/jc.2009-2631

[10]   Dai, H., Lu, L., Xing, X.-P., Wang, L.-J., Duan, L., Jiang, J., Zhu, L., Li, M., Song, A.-L., Yang, G.-H., Yu, Q., Tian, Q.-J., Zhou, Y.-Z. and Lu, Z.-L. (2018) Efficacy of Medium Dose Dexamethasone Androgen Suppression Test in the Diagnosis of Female Hyperandrogenism. National Medical Journal of China, 98, 2073-2077.

[11]   Swain, J., Sharma, S., Prakash, V., Agrawal, N.K. and Singh, S.K. (2013) Steroid Cell Tumor: A Rare Cause of Hirsutism in a Female. Endocrinology, Diabetes & Metabolism Case Reports, 2013, Article ID: 13-0030.
https://doi.org/10.1530/EDM-13-0030

[12]   Kozan, P., Chalasani, S., Handelsman, D.J., Pike, A.H. and Crawford, B.A. (2014) A Leydig Cell Tumor of the Ovary Resulting in Extreme Hyperandrogenism, Erythrocytosis, and Recurrent Pulmonary Embolism. The Journal of Clinical Endocrinology & Metabolism, 99, 12-17.
https://doi.org/10.1210/jc.2013-3108

[13]   Souto, S.B., Baptista, P.V., Braga, D.C. and Carvalho, D. (2014) Ovarian Leydig Cell Tumor in a Post-Menopausal Patient with Severe Hyperandrogenism. Arquivos Brasileiros de Endocrinologia & Metabologia, 58, 68-75.
https://doi.org/10.1590/0004-2730000002461

[14]   Yetkin, D.O., Demirsoy, E.T. and Kadioglu, P. (2011) Pure Leydig Cell Tumour of the Ovary in a Post-Menopausal Patient with Severe Hyperandrogenism and Erythrocytosis. Gynecological Endocrinology, 27, 237-240.
https://doi.org/10.3109/09513590.2010.490611

[15]   Nardo, L.G., Ray, D.W., Laing, I., Williams, C., McVey, R.J. and Seif, M.W. (2005) Ovarian Leydig Cell Tumor in a Peri-Menopausal Woman with Severe Hyperandrogenism and Virilization. Gynecological Endocrinology, 21, 238-241.
https://doi.org/10.1080/09513590500369005

[16]   Elhassan, Y.S., Idkowiak, J., Smith, K., Asia, M., Gleeson, H., Webster, R., Arlt, W. and O’Reilly, M.W. (2018) Causes, Patterns, and Severity of Androgen Excess in 1205 Consecutively Recruited Women. The Journal of Clinical Endocrinology & Metabolism, 103, 1214-1223.
https://doi.org/10.1210/jc.2017-02426

[17]   Markopoulos, M.C., Kassi, E., Alexandraki, K.I., Mastorakos, G. and Kaltsas, G. (2015) Hyperandrogenism after Menopause. European Journal of Endocrinology, 172, R79-R91. https://doi.org/10.1530/EJE-14-0468

[18]   Dennedy, M.C., Smith, D., O’Shea, D. and McKenna, T.J. (2010) Investigation of Patients with Atypical or Severe Hyperandrogenaemia Including Androgen-Secreting Ovarian Teratoma. European Journal of Endocrinology, 162, 213-220.
https://doi.org/10.1530/EJE-09-0576

[19]   Yildiz, B.O. (2006) Diagnosis of Hyperandrogenism: Clinical Criteria. Best Practice & Research Clinical Endocrinology & Metabolism, 20, 167-176.
https://doi.org/10.1016/j.beem.2006.02.004

[20]   Fanta, M., Fischerova, D., Indrielle-Kelly, T., Koliba, P., Zdenkova, A., Burgetova, A. and Vrbikova, J. (2018) Diagnostic Pitfalls in Ovarian Androgen-Secreting (Leydig Cell) Tumours: Case Series. Journal of Obstetrics and Gynaecology, 14, 1-6.

[21]   Levens, E.D., Whitcomb, B.W., Csokmay, J.M. and Nieman, L.K. (2009) Selective Venous Sampling for Androgen-Producing Ovarian Pathology. Clinical endocrinology, 70, 606-614.
https://doi.org/10.1111/j.1365-2265.2008.03389.x

[22]   Peigne, M., Villers-Capelle, A., Robin, G. and Dewailly, D. (2013) Hyperandrogenism in Women. La Presse Médicale, 42, 1487-1499.

[23]   Smeets, E.E., Span, P.N., van Herwaarden, A.E., Wevers, R.A., Hermus, A.R., Sweep, F.C. and Claahsen-van der Grinten, H.L.(2015) Molecular Characterization of Testicular Adrenal Rest Tumors in Congenital Adrenal Hyperplasia: Lesions with Both Adrenocortical and Leydig Cell Features. The Journal of Clinical Endocrinology & Metabolism, 100, E524-E530.
https://doi.org/10.1210/jc.2014-2036

[24]   Hishiki, T., Kazukawa, I., Saito, T., Terui, K., Mitsunaga, T., Nakata, M., Matsuura, G., Minagawa, M., Kohno, Y. and Yoshida, H. (2008) Diagnosis of Adrenocortical Tumor in a Neonate by Detection of Elevated Blood 17-Hydroxyprogesterone measured as a Routine Neonatal Screening for Congenital Adrenal Hyperplasia: A Case Report. Journal of Pediatric Surgery, 43, e19-e22.
https://doi.org/10.1016/j.jpedsurg.2008.05.023

[25]   Erem, C. (2013) Update on Idiopathic Hirsutism: Diagnosis and Treatment. Acta Clinica Belgica, 68, 268-274.
https://doi.org/10.2143/ACB.3267

[26]   Bonakdaran, S., Kiafar, B. and Barazandeh, A.F. (2016) Evaluation of Insulin Resistance in Idiopathic Hirsutism Compared with Polycystic Ovary Syndrome Patients and Healthy Individuals. Australasian Journal of Dermatology, 57, e1-e4.
https://doi.org/10.1111/ajd.12276

[27]   Severi, S., Galli, A. and Forleo, R. (1967) Free Testosterone and Epitestosterone and Glucosiduronates in the Urine of Females. 3. Test of Adrenal Inhibition with Dexamethasone. Folia endocrinologica, 20, 66-80.

[28]   Pascale, M.M., Pugeat, M., Roberts, M., Rousset, H., Dechaud, H., Dutrieuxberger, N. and Tourniaire, J. (1994) Androgen Suppressive Effect of Gnrh Agonist in Ovarian Hyperthecosis and Virilizing Tumors. Clinical Endocrinology, 41, 571-576.
https://doi.org/10.1111/j.1365-2265.1994.tb01820.x

[29]   Pecori Giraldi, F., Pivonello, R., Ambrogio, A.G., De Martino, M.C., De Martin, M., Scacchi, M., Colao, A., Toja, P.M., Lombardi, G. and Cavagnini, F. (2007) The Dexamethasone-Suppressed Corticotropin-Releasing Hormone Stimulation Test and the Desmopressin Test to Distinguish Cushing’s Syndrome from Pseudo-Cushing’s States. Clinical Endocrinology, 66, 251-257.
https://doi.org/10.1111/j.1365-2265.2006.02717.x

 
 
Top